MEDIX, God. 18 Br. 100  •  Pregledni članak  •  Onkologija HR ENG

Novosti u onkološkom liječenjuNew approaches in cancer treatment

Eduard Vrdoljak, Lidija Bošković, Branka Petrić Miše, Tihana Boraska Jelavić, Jelena Viculin, Ante Strikić, Marija Ban

Svjedoci smo znatnih, gotovo svakodnevnih promjena i poboljšanja u sustavnom liječenju solidnih tumora. Na krilima molekularne onkologije, otkrivanjem genskih specifičnosti, osobitosti pojedinih tumora, razvile su se i razvijaju se različite, nove terapijske opcije i modaliteti liječenja. Inhibicijom glasničkih puteva, čimbenika rasta ili gena koji su odgovorni za nekontrolirani rast tumora, relativno selektivno postiže se značajan terapijski odgovor osjetljivih tumora te produljuje život bolesnika. Tijekom prošle i ove godine stručna je javnost mogla svjedočiti velikim onkološkim novostima u sustavnome onkološkom liječenju tumora, osobito raka dojke, pluća, jajnika, želuca, gastrointestinalnih stromalnih tumora (GIST), neuroendokrinih tumora gušterače, kolorektalnoga raka, hepatocelularnoga karcinoma, raka prostate, raka bubrega, sarkoma, melanoma, tumora središnjega živčanog sustava te raka štitnjače. 

Ključne riječi:
17-(3-piridil)-5,16-androstadien-3beta-acetat; aflibercept; antitumorski protokoli; ARQ 197; aksitinib; bevacizumab; krizotinib; everolimus; imatinib; ipilimumab; N-(4-bromo- 2-fluorofenil)-6-metoksi-7-((1-metilpiperidin-4-il)metoksi)kinazolin-4-amin; novotvorine; pazopanib; pertuzumab; PLX4032; ridaforolimus; sunitinib; trastuzumab

Članak u cijelosti pročitajte u tiskanom izdanju MEDIX, God. 18 Br. 100

We are witnessing changes and improvements in the treatment of solid tumors almost on daily basis. Due to advancements in molecular oncology and discoveries of the genetic specificities and signatures of specific tumor types, we have developed and continue to develop new treatment modalities. By inhibiting transduction pathways, growth factors or genes responsible for uncontrolled growth of tumors, we can achieve a substantial treatment response of sensitive tumors in a relatively selective manner, which leads to survival benefits for oncology patients. During the last year and a half, there have been significant breakthroughs in the systemic treatment of different solid tumors including breast cancer, lung cancer, ovarian cancer, gastric cancer, gastrointestinal stromal tumors (GIS T), neuroendocrine pancreatic tumors, colorectal cancer, hepatocelullar cancer, prostate cancer, renal cancer, sarcomas, melanomas, CNS tumors and thyroid cancer. 

Key words:
17-(3-pyridyl)-5,16-androstadien-3beta-acetate; aflibercept; antineoplastic protocols; ARQ 197; axitinib; bevacizumab; crizotinib; everolimus; imatinib; ipilimumab; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin- 4-yl)methoxy)quinazolin-4-amine; neoplasms; pazopanib; pertuzumab; PLX4032; ridaforolimus; sunitinib; trastuzumab